{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:43:35Z","timestamp":1790959415027,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11046-025-00974-2","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:43:03Z","timestamp":1755254583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Clinical Characteristics and Outcomes of Candida (Candidozyma)\u00a0auris vs. Non-C. auris Candidemia in Non-neutropenic Patients in South India"],"prefix":"10.1007","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4522-8752","authenticated-orcid":false,"given":"Jui","family":"Athavale-Wad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Sethuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Senthur","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Balaguru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logesh","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatasubramanian","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"974_CR1","doi-asserted-by":"publisher","unstructured":"A. Soriano et al., \u201cInvasive candidiasis: current clinical challenges and unmet needs in adult populations,\u201d 2023, Oxford University Press. https:\/\/doi.org\/10.1093\/jac\/dkad139.","DOI":"10.1093\/jac\/dkad139"},{"key":"974_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057","author":"F Bongomin","year":"2017","unstructured":"Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases\u2014estimate precision. Mdpi AG. 2017. https:\/\/doi.org\/10.3390\/jof3040057.","journal-title":"Mdpi AG"},{"key":"974_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3603-2","author":"A Chakrabarti","year":"2015","unstructured":"Chakrabarti A, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med. 2015. https:\/\/doi.org\/10.1007\/s00134-014-3603-2.","journal-title":"Intensive Care Med"},{"key":"974_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac603","author":"A Ray","year":"2022","unstructured":"Ray A, AdarshAayilliath K, Banerjee S, Chakrabarti A, Denning DW. Burden of serious fungal infections in India. Open Forum Infect Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofac603.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"974_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/ijmm.IJMM_20_112","volume":"38","author":"H Kaur","year":"2020","unstructured":"Kaur H, et al. Candidaemia in a tertiary care centre of developing country: Monitoring possible change in spectrum of agents and antifungal susceptibility. Indian J Med Microbiol. 2020;38(1):109\u201315. https:\/\/doi.org\/10.4103\/ijmm.IJMM_20_112.","journal-title":"Indian J Med Microbiol"},{"key":"974_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390100145030","author":"SB Wey","year":"1989","unstructured":"Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med. 1989. https:\/\/doi.org\/10.1001\/archinte.1989.00390100145030.","journal-title":"Arch Intern Med"},{"key":"974_CR7","doi-asserted-by":"publisher","DOI":"10.1086\/378745","author":"O Gudlaugsson","year":"2003","unstructured":"Gudlaugsson O, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Inf Diseases. 2003. https:\/\/doi.org\/10.1086\/378745.","journal-title":"Clin Inf Diseases"},{"key":"974_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13177","author":"FB Cornely","year":"2020","unstructured":"Cornely FB, et al. Attributable mortality of candidemia after introduction of echinocandins. Mycoses. 2020. https:\/\/doi.org\/10.1111\/myc.13177.","journal-title":"Mycoses"},{"key":"974_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106229","author":"J Salmanton-Garc\u00eda","year":"2024","unstructured":"Salmanton-Garc\u00eda J, et al. Attributable mortality of candidemia\u2014Results from the ECMM Candida III multinational European Observational Cohort Study. J Infection. 2024. https:\/\/doi.org\/10.1016\/j.jinf.2024.106229.","journal-title":"J Infection"},{"key":"974_CR10","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-23748","author":"S Sridharan","year":"2021","unstructured":"Sridharan S, Gopalakrishnan R, Nambi PS, Kumar S, Sethuraman N, Ramasubramanian V. Clinical profile of non-neutropenic patients with invasive candidiasis: a retrospective study in a tertiary care center. Indian J Critical Care Med. 2021. https:\/\/doi.org\/10.5005\/jp-journals-10071-23748.","journal-title":"Indian J Critical Care Med"},{"key":"974_CR11","doi-asserted-by":"publisher","DOI":"10.5005\/JP-JOURNALS-10071-24152","author":"PS Prayag","year":"2022","unstructured":"Prayag PS, Patwardhan S, Panchakshari S, Rajhans PA, Prayag A. The dominance of Candida (Candidozyma) auris: a single-center experience of 79 episodes of candidemia from Western India. Indian J Crit Care Med. 2022. https:\/\/doi.org\/10.5005\/JP-JOURNALS-10071-24152.","journal-title":"Indian J Crit Care Med"},{"key":"974_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.01.004","author":"PS Shastri","year":"2020","unstructured":"Shastri PS, Shankarnarayan SA, Oberoi J, Rudramurthy SM, Wattal C, Chakrabarti A. Candida (Candidozyma) auris candidaemia in an intensive care unit\u2014prospective observational study to evaluate epidemiology, risk factors, and outcome. J Crit Care. 2020. https:\/\/doi.org\/10.1016\/j.jcrc.2020.01.004.","journal-title":"J Crit Care"},{"key":"974_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2008.00083.x","author":"K Satoh","year":"2009","unstructured":"Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida (Candidozyma) auris sp. nov, a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009. https:\/\/doi.org\/10.1111\/j.1348-0421.2008.00083.x.","journal-title":"Microbiol Immunol"},{"key":"974_CR14","doi-asserted-by":"publisher","DOI":"10.3201\/eid1910.130393","author":"A Chowdhary","year":"2013","unstructured":"Chowdhary A, et al. New clonal strain of Candida (Candidozyma) auris, Delhi, India. Emerg Infect Dis. 2013. https:\/\/doi.org\/10.3201\/eid1910.130393.","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"974_CR15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1056\/NEJMra2402635","volume":"391","author":"MS Lionakis","year":"2024","unstructured":"Lionakis MS, Chowdhary A. Candida (Candidozyma) auris Infections. N Engl J Med. 2024;391(20):1924\u201335. https:\/\/doi.org\/10.1056\/NEJMra2402635.","journal-title":"N Engl J Med"},{"key":"974_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.10.018","author":"MM Ninan","year":"2020","unstructured":"Ninan MM, Sahni RD, Chacko B, Balaji V, Michael JS. Candida (Candidozyma) auris: Clinical profile, diagnostic challenge and susceptibility pattern: experience from a tertiary-care centre in South India. J Glob Antimicrob Resist. 2020. https:\/\/doi.org\/10.1016\/j.jgar.2019.10.018.","journal-title":"J Glob Antimicrob Resist"},{"key":"974_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx034","author":"SM Rudramurthy","year":"2017","unstructured":"Rudramurthy SM, et al. Candida (Candidozyma) auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicro Chem. 2017. https:\/\/doi.org\/10.1093\/jac\/dkx034.","journal-title":"J Antimicro Chem"},{"key":"974_CR18","unstructured":"ICMR; 2017, \u201cIndian Council of Medical Research (ICMR). Candida (Candidozyma) auris in healthcare settings\u2014India. New Delhi, India,\u201d 2017."},{"key":"974_CR19","doi-asserted-by":"publisher","DOI":"10.7326\/M22-3469","author":"M Lyman","year":"2023","unstructured":"Lyman M, et al. Worsening Spread of Candida (Candidozyma) auris in the United States, 2019 to 2021. Ann Intern Med. 2023. https:\/\/doi.org\/10.7326\/M22-3469.","journal-title":"Ann Intern Med"},{"issue":"4","key":"974_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dkx480","volume":"73","author":"A Chowdhary","year":"2018","unstructured":"Chowdhary A, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida (Candidozyma) auris isolates (2009\u201317) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891\u20139. https:\/\/doi.org\/10.1093\/jac\/dkx480.","journal-title":"J Antimicrob Chemother"},{"key":"974_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir111","author":"CA Kauffman","year":"2011","unstructured":"Kauffman CA, Fisher JF, Sobel JD, Newman CA. Candida urinary tract infections\u2014Diagnosis. Clin Inf Diseases. 2011. https:\/\/doi.org\/10.1093\/cid\/cir111.","journal-title":"Clin Inf Diseases"},{"key":"974_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix033","author":"G Cuervo","year":"2017","unstructured":"Cuervo G, et al. Echinocandins compared to fluconazole for candidemia of a urinary tract source: a propensity score analysis. Clin Inf Diseases. 2017. https:\/\/doi.org\/10.1093\/cid\/cix033.","journal-title":"Clin Inf Diseases"},{"key":"974_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jof8020123","author":"M Elbaz","year":"2022","unstructured":"Elbaz M, Chikly A, Meilik R, Ben-Ami R. Frequency and Clinical Features of Candida Bloodstream Infection Originating in the Urinary Tract. J Fungi. 2022. https:\/\/doi.org\/10.3390\/jof8020123.","journal-title":"J Fungi"},{"issue":"5","key":"974_CR24","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1080\/21548331.2018.1538623","volume":"46","author":"J Pem\u00e1n","year":"1995","unstructured":"Pem\u00e1n J, Ruiz-Gait\u00e1n A. Candidemia from urinary tract source: the challenge of candiduria. Hosp Pract. 1995;46(5):2018. https:\/\/doi.org\/10.1080\/21548331.2018.1538623.","journal-title":"Hosp Pract"},{"key":"974_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00585-6","author":"M Bassetti","year":"2022","unstructured":"Bassetti M, et al. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infect Dis Ther. 2022. https:\/\/doi.org\/10.1007\/s40121-021-00585-6.","journal-title":"Infect Dis Ther"},{"key":"974_CR26","unstructured":"CLSI, Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th ed CLSI M27. Wayne, PA: Clinical and Laboratory Standards Institute, 2017."},{"key":"974_CR27","unstructured":"CDC, \u201cAntifungal Susceptibility Testing for C. auris.\u201d Accessed: Mar. 10, 2025. [Online]. Available: https:\/\/www.cdc.gov\/candida-auris\/hcp\/laboratories\/antifungal-susceptibility-testing.html"},{"key":"974_CR28","unstructured":"CLSI, Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 4th ed CLSI M57S. Clinical and Laboratory Standards Institute, 2022."},{"key":"974_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00749-7","author":"OA Cornely","year":"2025","unstructured":"Cornely OA, et al. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2025. https:\/\/doi.org\/10.1016\/S1473-3099(24)00749-7.","journal-title":"Lancet Infect Dis"},{"key":"974_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.02.012","author":"M Mikulska","year":"2024","unstructured":"Mikulska M, et al. Lower (1,3)-beta-D-glucan sensitivity and in vitro levels in Candida (Candidozyma) auris and Candida parapsilosis strains. Clin Microbiol Inf. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2024.02.012.","journal-title":"Clin Microbiol Inf"},{"key":"974_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myae122","author":"GR Thompson III","year":"2024","unstructured":"Thompson GR III, et al. Mortality patterns in candidemia: insights from a multispecies analysis using a global research network. Med Mycol. 2024. https:\/\/doi.org\/10.1093\/mmy\/myae122.","journal-title":"Med Mycol"},{"key":"974_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1160841","author":"MN Sumana","year":"2023","unstructured":"Sumana MN. Retrospective analysis on distribution and antifungal susceptibility profile of Candida in clinical samples: a study from Southern India. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.1160841.","journal-title":"Front Public Health"},{"key":"974_CR33","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.ijid.2023.05.057","volume":"134","author":"YA Tan","year":"2023","unstructured":"Tan YA, Thangarajah P, Zaidan NZ. Species distribution and microbiological profile of candidemia cases in a tertiary hospital in Melaka, Malaysia. Int J Infect Dis. 2023;134:S16. https:\/\/doi.org\/10.1016\/j.ijid.2023.05.057.","journal-title":"Int J Infect Dis"},{"key":"974_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myac071","author":"T Kajihara","year":"2022","unstructured":"Kajihara T, et al. Distribution, trends, and antifungal susceptibility of Candida species causing candidemia in Japan, 2010\u20132019: a retrospective observational study based on national surveillance data. Med Mycol. 2022. https:\/\/doi.org\/10.1093\/mmy\/myac071.","journal-title":"Med Mycol"},{"issue":"1","key":"974_CR35","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1080\/21505594.2022.2123325","volume":"13","author":"H Bilal","year":"2022","unstructured":"Bilal H, et al. Distribution and antifungal susceptibility pattern of Candida species from mainland China: a systematic analysis. Virulence. 2022;13(1):1573\u201389. https:\/\/doi.org\/10.1080\/21505594.2022.2123325.","journal-title":"Virulence"},{"key":"974_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1469-0691.12539","volume":"20","author":"J Guinea","year":"2014","unstructured":"Guinea J. Global trends in the distribution of <em>Candida<\/em> species causing candidemia. Clin Microbiol Infect. 2014;20:5\u201310. https:\/\/doi.org\/10.1111\/1469-0691.12539.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"974_CR37","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1186\/s12879-024-10007-w","volume":"24","author":"HSA Aziz","year":"2024","unstructured":"Aziz HSA, Ismail DK, Mohammed NSA, Elgendy MO, Bassiouny DM. Distribution and antifungal susceptibility profiles of Candida species isolated from candidemia patients admitted to Egyptian tertiary hospitals: a cross-sectional study. BMC Infect Dis. 2024;24(1):1177. https:\/\/doi.org\/10.1186\/s12879-024-10007-w.","journal-title":"BMC Infect Dis"},{"key":"974_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx444","author":"F Lamoth","year":"2018","unstructured":"Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrobial Chemotherapy. 2018. https:\/\/doi.org\/10.1093\/jac\/dkx444.","journal-title":"J Antimicrobial Chemotherapy"},{"key":"974_CR39","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2021.235","author":"E Rajni","year":"2022","unstructured":"Rajni E, Chaudhary P, Garg VK, Sharma R, Malik M. A complete clinico-epidemiological and microbiological profile of candidemia cases in a tertiary-care hospital in Western India. Antimicrobial Stewardship Healthc Epidemiol. 2022. https:\/\/doi.org\/10.1017\/ash.2021.235.","journal-title":"Antimicrobial Stewardship Healthc Epidemiol"},{"key":"974_CR40","doi-asserted-by":"publisher","DOI":"10.4103\/ijccm.IJCCM_4_18","author":"N Bansal","year":"2018","unstructured":"Bansal N, et al. Experience with \u03b2-D-Glucan assay in the management of critically ill patients with high risk of invasive candidiasis: an observational study. Indian J Critical Care Med. 2018. https:\/\/doi.org\/10.4103\/ijccm.IJCCM_4_18.","journal-title":"Indian J Critical Care Med"},{"key":"974_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab452","author":"E Rajni","year":"2021","unstructured":"Rajni E, et al. A High Frequency of Candida (Candidozyma) auris Blood Stream Infections in Coronavirus Disease 2019 Patients Admitted to Intensive Care Units, Northwestern India: A Case Control Study. Open Forum Infect Dis. 2021. https:\/\/doi.org\/10.1093\/ofid\/ofab452.","journal-title":"Open Forum Infect Dis"},{"key":"974_CR42","doi-asserted-by":"publisher","DOI":"10.7860\/njlm\/2022\/50713.2576","author":"P Rudrapathy","year":"2022","unstructured":"Rudrapathy P, Samuel S, Murugesan S. Microbiological Profile and antibiotic resistance of bloodstream infections among cancer patients at a tertiary care cancer centre in North Kerala, India. Nat J Lab Med. 2022. https:\/\/doi.org\/10.7860\/njlm\/2022\/50713.2576.","journal-title":"Nat J Lab Med"},{"key":"974_CR43","doi-asserted-by":"publisher","unstructured":"Vaseghi N et al., \u201cGlobal prevalence and subgroup analyses of coronavirus disease (COVID-19) associated Candida (Candidozyma) auris infections (CACa): A systematic review and meta-analysis,\u201d John Wiley and Sons Inc. https:\/\/doi.org\/10.1111\/myc.13471. (2022)","DOI":"10.1111\/myc.13471"},{"issue":"11","key":"974_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.cmi.2020.02.001","volume":"26","author":"V Garcia-Bustos","year":"2020","unstructured":"Garcia-Bustos V, Salavert M, Ruiz-Gait\u00e1n AC, Caba\u00f1ero-Navalon MD, Sigona-Giangreco IA, Pem\u00e1n J. A clinical predictive model of candidaemia by Candida (Candidozyma) auris in previously colonized critically ill patients. Clin Microbiol Infect. 2020;26(11):1507\u201313. https:\/\/doi.org\/10.1016\/j.cmi.2020.02.001.","journal-title":"Clin Microbiol Infect"},{"key":"974_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2024.100539","author":"DR Joshi","year":"2024","unstructured":"Joshi DR, et al. Epidemiology and outcomes of infections during extracorporeal membrane oxygenation in adult patients with COVID-19 ARDS-a single center study. Indian J Med Microbiol. 2024. https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100539.","journal-title":"Indian J Med Microbiol"},{"issue":"2","key":"974_CR46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.5173\/ceju.2019.1909","volume":"72","author":"M Gajd\u00e1cs","year":"2019","unstructured":"Gajd\u00e1cs M, D\u00f3czi I, \u00c1br\u00f3k M, L\u00e1z\u00e1r A, Buri\u00e1n K. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: results from a 10-year retrospective survey. Cent Europ J Urol. 2019;72(2):209\u201314. https:\/\/doi.org\/10.5173\/ceju.2019.1909.","journal-title":"Cent Europ J Urol"},{"key":"974_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9120898","author":"N Griffith","year":"2020","unstructured":"Griffith N, Danziger L. Candida (Candidozyma) auris urinary tract infections and possible treatment. MDPI AG. 2020. https:\/\/doi.org\/10.3390\/antibiotics9120898.","journal-title":"MDPI AG"},{"key":"974_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153247","author":"P Vergidis","year":"2016","unstructured":"Vergidis P, et al. Intra-abdominal candidiasis: the importance of early source control and antifungal treatment. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0153247.","journal-title":"PLoS ONE"},{"key":"974_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.578","author":"J OseiSekyere","year":"2018","unstructured":"OseiSekyere J. Candida (Candidozyma) auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiologyopen. 2018. https:\/\/doi.org\/10.1002\/mbo3.578.","journal-title":"Microbiologyopen"},{"key":"974_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03081","author":"L Rossato","year":"2018","unstructured":"Rossato L, Colombo AL. Candida (Candidozyma) auris: What have we learned about its mechanisms of pathogenicity? Front Med SA. 2018. https:\/\/doi.org\/10.3389\/fmicb.2018.03081.","journal-title":"Front Med SA"},{"issue":"4","key":"974_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mSphere.00189-16","volume":"1","author":"AM Borman","year":"2016","unstructured":"Borman AM, Szekely A, Johnson EM. Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida (Candidozyma) auris and Other Key Pathogenic Candida Species. MSphere. 2016;1(4):10\u2013128.","journal-title":"MSphere."},{"key":"974_CR52","doi-asserted-by":"publisher","unstructured":"Daneshnia F et al, \u201cWorldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap,\u201d 2023. https:\/\/doi.org\/10.1016\/S2666-5247(23)00067-8.","DOI":"10.1016\/S2666-5247(23)00067-8"},{"key":"974_CR53","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00053-22","author":"SE Jacobs","year":"2022","unstructured":"Jacobs SE, et al. Candida (Candidozyma) auris Pan-Drug-Resistant to Four Classes of Antifungal Agents. Antimicrob Agents Chemother. 2022. https:\/\/doi.org\/10.1128\/aac.00053-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"974_CR54","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/cid\/ciaa1943","volume":"72","author":"F Lamoth","year":"2021","unstructured":"Lamoth F, et al. Assessment of the Role of 1,3-\u03b2-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults. Clin Infect Dis. 2021;72:S102\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa1943.","journal-title":"Clin Infect Dis"},{"key":"974_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz555","author":"C Agnelli","year":"2020","unstructured":"Agnelli C, et al. Clinical Relevance and Prognostic Value of Persistently Negative (1,3)-\u03b2-D-Glucan in Adults with Candidemia: a 5-year Experience in a Tertiary Hospital. Clin Inf Diseases. 2020. https:\/\/doi.org\/10.1093\/cid\/ciz555.","journal-title":"Clin Inf Diseases"},{"key":"974_CR56","unstructured":"Mutuyimana J, Hashemi H, Lander N, Perera N, Swann A, \u201cA service evaluation of the role of serum (1,3) beta-D- Glucan testing in Intensive Care patients at risk for Invasive Candidiasis,\u201d Mycoses, 60(2), 2017."},{"key":"974_CR57","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00773-12","author":"CR Sims","year":"2012","unstructured":"Sims CR, Jaijakul S, Mohr J, Rodriguez J, Finkelman M, Ostrosky-Zeichner L. Correlation of clinical outcomes with \u03b2-glucan levels in patients with invasive candidiasis. J Clin Microbiol. 2012. https:\/\/doi.org\/10.1128\/JCM.00773-12.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"974_CR58","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10096-021-04394-0","volume":"41","author":"M Kutlu","year":"2022","unstructured":"Kutlu M, et al. Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey. Eur J Clin Microbiol Infect Dis. 2022;41(4):597\u2013607. https:\/\/doi.org\/10.1007\/s10096-021-04394-0.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"974_CR59","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13054-016-1229-1","volume":"20","author":"J-A Paiva","year":"2016","unstructured":"Paiva J-A, et al. Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care. 2016;20(1):53. https:\/\/doi.org\/10.1186\/s13054-016-1229-1.","journal-title":"Crit Care"},{"key":"974_CR60","doi-asserted-by":"crossref","unstructured":"IY Jung et al., \u201cA multicenter retrospective analysis of the antifungal susceptibility patterns of Candida species and the predictive factors of mortality in South Korean patients with candidemia,\u201d Medicine, 99(11), 2020, [Online]. Available: https:\/\/journals.lww.com\/md-journal\/fulltext\/2020\/03130\/a_multicenter_retrospective_analysis_of_the.67.aspx","DOI":"10.1097\/MD.0000000000019494"},{"key":"974_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05719-8","author":"N Asai","year":"2021","unstructured":"Asai N, et al. Combination of Sequential Organ Failure Assessment (SOFA) score and Charlson Comorbidity Index (CCI) could predict the severity and prognosis of candidemia more accurately than the Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) score. BMC Infect Dis. 2021. https:\/\/doi.org\/10.1186\/s12879-020-05719-8.","journal-title":"BMC Infect Dis"},{"key":"974_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1097574","author":"W Li","year":"2023","unstructured":"Li W, et al. A scoring system based on novel biomarkers and clinical risk factors to predict invasive candidiasis in immunocompetent critically ill patients. Front Microbiol. 2023. https:\/\/doi.org\/10.3389\/fmicb.2023.1097574.","journal-title":"Front Microbiol"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-025-00974-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11046-025-00974-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-025-00974-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T12:06:11Z","timestamp":1758974771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11046-025-00974-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s11046-025-00974-2","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study was conducted as per ICH-GCP, National Ethical Guidelines for Biomedical and Health Research involving Human Participants (ICMR 2017) and New drugs and Clinical Trial Rules, March 2019. The approval was granted by Institutional Ethics Committee- Bio Medical Research (Date 28\u201302-2024\/ No: AMH-C-S-012\/02\u201324).As the study was conducted retrospectively using medical records and no personal and identifying details of the patients were used\/ mentioned, a waiver of consent was approved by the Institutional ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"72"}}